Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

220.91
+5.402.51%
Post-market: 220.910.00000.00%18:10 EST
Volume:1.13M
Turnover:249.76M
Market Cap:10.87B
PE:-144.39
High:222.37
Open:217.82
Low:216.88
Close:215.51
52wk High:222.37
52wk Low:91.86
Shares:49.22M
Float Shares:48.62M
Volume Ratio:1.54
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5300
EPS(LYR):0.2004
ROE:-2.19%
ROA:4.33%
PB:3.19
PE(LYR):1,102.30

Loading ...

Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Charles River Labs (CRL) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
Nov 07, 2025

Evercore ISI Sticks to Its Buy Rating for Charles River Labs (CRL)

TIPRANKS
·
Nov 06, 2025

This Charles River Laboratories Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Benzinga_recent_news
·
Nov 06, 2025

Charles River Labs Raised to Outperform From Neutral by Baird

Dow Jones
·
Nov 06, 2025

Charles River Labs : Barclays Raises Target Price to $210 From $195

THOMSON REUTERS
·
Nov 06, 2025

Baird Upgrades Charles River Laboratories International to Outperform From Neutral, Adjusts PT to $199 From $178

MT Newswires Live
·
Nov 06, 2025

U.S. RESEARCH ROUNDUP-Acadia Pharmaceuticals, Applovin, Centuri Holdings

Reuters
·
Nov 06, 2025

Charles River Laboratories International Inc : Baird Raises to Outperform Rating; Raises Target Price to $199 From $178

THOMSON REUTERS
·
Nov 06, 2025

Charles River Laboratories International Inc : JP Morgan Raises Target Price to $165 From $160

THOMSON REUTERS
·
Nov 06, 2025

Charles River Laboratories International Inc. Stock Falls 5.7%, Underperforms Peers

Dow Jones
·
Nov 06, 2025

Charles River Beat Expectations But Why Is The Stock Falling?

Benzinga
·
Nov 06, 2025

Analysts’ Top Healthcare Picks: Charles River Labs (CRL), Vaxcyte (PCVX)

TIPRANKS
·
Nov 06, 2025

Charles River Laboratories International Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 05, 2025

Stock Track | Charles River Laboratories Plummets 7.41% as Strategic Review Unveils Asset Sales and Cost-Cutting Measures

Stock Track
·
Nov 05, 2025

Charles River provides update on strategic review

TIPRANKS
·
Nov 05, 2025

Charles River Laboratories Exec Says Haven't Seen Any Impact From Biosecure Act

THOMSON REUTERS
·
Nov 05, 2025

Charles River Exec Says Many Global Biopharma Clients Appear to Have Progressed Through Restructuring Efforts, and Biotech Funding Environment Showed Signs of Improvement Throughout Q3

THOMSON REUTERS
·
Nov 05, 2025

Charles River Exec Says Have Not Experienced Any Meaningful Impact From Nih Budget Uncertainty or Government Shutdown to Date

THOMSON REUTERS
·
Nov 05, 2025

Charles River Exec Says NOW Expect Manufacturing Revenue to Be Flat to Slightly Lower on Organic Basis in 2025, Compared to Prior Outlook of Approximately Flat

THOMSON REUTERS
·
Nov 05, 2025

Charles River Laboratories International Exec Says Will Strive to Complete Any Potential Divestitures by Middle of 2026 - Conf Call

THOMSON REUTERS
·
Nov 05, 2025